 InflaRx IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today interim results from the first 30 patients treated in the adaptive randomized Phase IIIII trial in patients with severe COVID-19 pneumonia. The Phase II part of the study evaluated IFX-1 treatment plus best supportive care compared to best supportive care alone for up to 28 days. Relative change from baseline to day 5 in oxygenation index defined as PaO2FiO2 ratio was assessed as the primary endpoint along with additional clinical parameters until day 28. 